The FINANCIAL — Janssen Pharmaceuticals announced the U.S. Food and Drug Administration has approved XARELTO, an oral anticoagulant, for the treatment of deep vein thrombosis and/or pulmonary embolism ...

NEW YORK (AP) — Johnson & Johnson’s Xarelto received an expanded indication as the Food and Drug Administration on Friday approved the blood thinner both to treat and to reduce the risk of recurrence ...

The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine. (April 5, 2012) 366;14. The traditional treatment for patients ...

September 23, 2011 (London, United Kingdom) — Advisors for the European Medicines Agency (EMA) have paved the way for two new indications for rivaroxaban (Xarelto, Bayer) in Europe. The EMA's ...

FRANKFURT, May 28 (Reuters) - Bayer AG said it has submitted anti-clotting drug Xarelto for marketing authorisation in Japan for the treatment of deep vein thrombosis and pulmonary embolism, the ...

Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer 1 Previous studies such as SELECT-D and CONKO-11 demonstrated that changing from a low molecular weight ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

(Reuters) -Older adults taking Bayer AG's blockbuster blood thinner pill Xarelto for a common type of irregular heart rhythm had significantly higher rates of serious bleeding and stroke compared to ...

The phase 3 UNIVERSE study evaluated rivaroxaban oral suspension in patients aged 2 to 8 years with single ventricle physiology who had the Fontan procedure. New data were announced from a phase 3 ...

If the choice is made to anticoagulate patients with symptomatic isolated distal deep vein thrombosis (DVT), outcomes will be improved with 12 versus 6 weeks of treatment, the randomized, ...